Adicet Bio to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Adicet Bio (Nasdaq: ACET), a biotechnology firm, announced its participation in several virtual investor conferences in November and December 2020. These events include:

• H.C. Wainwright Conference on November 12, 2020, at 9:00 AM ET
• B. Riley Securities Panel on November 12, 2020, at 2:00 PM ET
• Stifel Healthcare Conference on November 17, 2020, at 3:20 PM ET
• Evercore ISI HealthCONx Conference on December 1, 2020, at 1:00 PM ET

Live audio webcasts will be available on the company's website, with archived replays for 30 days post-event.

MENLO PARK, Calif. and BOSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company management will participate in upcoming virtual investor conferences and events in November and December.

Details of the events are as follows:

H.C. Wainwright 6th Annual Israel Conference
Presentation on November 12, 2020 at 9:00 AM ET

B. Riley Securities’ Cell Therapy 2.0: Transforming Immune Cells to Mainstream Cancer Treatments at Society for Immunotherapy of Cancer Annual Meeting
Panel discussion on November 12, 2020 at 2:00 PM ET

Stifel 2020 Virtual Healthcare Conference
Presentation on November 17, 2020 at 3:20 PM ET

3rd Annual Evercore ISI HealthCONx Conference
Panel discussion on December 1, 2020 at 1:00 PM ET

Adicet management team will also participate in virtual investor meetings at these conferences.

Live audio webcasts of the presentations can be accessed on the Investors section of Adicet Bio’s website at https://investor.adicetbio.com. Archived replays will be available for 30 days following each event.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.  For more information, please visit our website at http://www.adicetbio.com.

Adicet Bio., Inc.
Investor and Media Contacts
Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com

FAQ

What events is Adicet Bio participating in for November 2020?

Adicet Bio is participating in several events, including the H.C. Wainwright Conference on November 12, B. Riley Securities Panel on the same day, the Stifel Healthcare Conference on November 17, and the Evercore ISI HealthCONx Conference on December 1.

What time is Adicet Bio's presentation at the H.C. Wainwright Conference?

Adicet Bio's presentation at the H.C. Wainwright Conference is scheduled for November 12, 2020, at 9:00 AM ET.

How can I access the webcasts of Adicet Bio's presentations?

Live audio webcasts of Adicet Bio's presentations can be accessed on the company's investor website, with archived replays available for 30 days after each event.

What is the focus of Adicet Bio's therapies?

Adicet Bio focuses on developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases.